CoChat

Accelerated Aging in HIV/AIDS: Novel Biomarkers of Senescent Human CD8+ T Cells

Open access

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Clinical evaluation of immune reconstitution and health status during HIV-1 infection and anti-retroviral therapy (ART) is largely based on CD4+ T cell counts and viral load, measures that fail to take into account the CD8+ T cell subset, known to show features of accelerated aging in HIV disease. Here, we compare adenosine deaminase (ADA), glucose uptake receptor 1 (GLUT1), and leucine-rich repeat neuronal 3 (LRRN3) to CD38 expression and telomerase activity, two strong predictors of HIV disease progression. Our analysis revealed that reduced ADA, telomerase activity and LRRN3 gene expression were significantly associated with high CD38 and HLA-DR in CD8+ T cells, with % ADA+ cells being the most robust predictor of CD8+ T cell activation. Our results suggest that ADA, LRRN3 and telomerase activity in CD8+ T cells may serve as novel, clinically relevant biomarkers of immune status in HIV-1 infection, specifically by demonstrating the degree to which CD8+ T cells have progressed to the end stage of replicative senescence. Since chronological aging itself leads to the accumulation of senescent CD8+ T cells, the prolonged survival and resultant increased age of the HIV+ population may synergize with the chronic immune activation to exacerbate both immune decline and age-associated pathologies. The identification and future validation of these new biomarkers may lead to fresh immune-based HIV treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0064702

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Low ecto-ADA expression correlates with high levels of activation markers. (a) Representative flow cytometry data of surface staining for ecto-ADA and CD8 molecules on T cells 4 days after stimulation with an allogeneic transformed B-cell line. Comparison between %ADA+ within the CD8+ T cell subset from HIV+ donors with low (top) and high activation (bottom) levels, defined by activation marker CD38 (2.1% and 18.2%, respectively). CD8+ T cells with low %CD38 had greater ecto-ADA expression (30.2%), as compared to those with high %CD38, who showed lower ADA (13.3%). (b) Representative histogram comparing the same donors as in panel (a). The dark lines represent the donor with high activation (18.2%), compared to the donor with low activation (2.1%). (c) Statistical analyses indicating a strong negative relationship between ecto-ADA expression and percentages of CD38+ and HLA-DR+ (r = −0.5441, p<0.0001), as well as number of CD38 molecules (r = −0.4766, p = 0.0004). (d) Significant positive correlation between CD8+ADA+ and CD8+ telomerase activity (r = 0.4012, p<0.0069).
Figure 1 Low ecto-ADA expression correlates with high levels of activation markers. (a) Representative flow cytometry data of surface staining for ecto-ADA and CD8 molecules on T cells 4 days after stimulation with an allogeneic transformed B-cell line. Comparison between %ADA+ within the CD8+ T cell subset from HIV+ donors with low (top) and high activation (bottom) levels, defined by activation marker CD38 (2.1% and 18.2%, respectively). CD8+ T cells with low %CD38 had greater ecto-ADA expression (30.2%), as compared to those with high %CD38, who showed lower ADA (13.3%). (b) Representative histogram comparing the same donors as in panel (a). The dark lines represent the donor with high activation (18.2%), compared to the donor with low activation (2.1%). (c) Statistical analyses indicating a strong negative relationship between ecto-ADA expression and percentages of CD38+ and HLA-DR+ (r = −0.5441, p<0.0001), as well as number of CD38 molecules (r = −0.4766, p = 0.0004). (d) Significant positive correlation between CD8+ADA+ and CD8+ telomerase activity (r = 0.4012, p<0.0069).CC BY · PubMed Central
Figure 2 LRRN3 mRNA expression is associated with increased expression of CD38+ and HLA-DR+. (a) Ex vivo CD8+ T cells from HIV+ donors were isolated using RosetteSep CD8+ T cell enrichment cocktail from whole blood. LRRN3 transcription in CD8+ T cells was compared for HIV+ donors with high and low levels of activation, defined by CD38 and HLA-DR. 36B4 was used as the housekeeping gene. There was a strong negative relationship between LRRN3 mRNA and percentages of CD38+ and HLA-DR+ cells (r = −0.36012, p = 0.0192). (b) Positive correlation between LRRN3 mRNA and CD3+ telomerase activity (r = 0.5988, p<0.0001) and CD8+ telomerase activity (r = 0.2724, p = 0.11). (c) Positive relationship between LRRN3 mRNA and %CD28+ within the CD8+ T cell subset (r = 0.3782, p = 0.0161), suggesting a potential modulatory role of LRRN3 on CD28 surface expression.
Figure 2 LRRN3 mRNA expression is associated with increased expression of CD38+ and HLA-DR+. (a) Ex vivo CD8+ T cells from HIV+ donors were isolated using RosetteSep CD8+ T cell enrichment cocktail from whole blood. LRRN3 transcription in CD8+ T cells was compared for HIV+ donors with high and low levels of activation, defined by CD38 and HLA-DR. 36B4 was used as the housekeeping gene. There was a strong negative relationship between LRRN3 mRNA and percentages of CD38+ and HLA-DR+ cells (r = −0.36012, p = 0.0192). (b) Positive correlation between LRRN3 mRNA and CD3+ telomerase activity (r = 0.5988, p<0.0001) and CD8+ telomerase activity (r = 0.2724, p = 0.11). (c) Positive relationship between LRRN3 mRNA and %CD28+ within the CD8+ T cell subset (r = 0.3782, p = 0.0161), suggesting a potential modulatory role of LRRN3 on CD28 surface expression.CC BY · PubMed Central
Figure 3 Telomerase activity is inversely correlated with activation biomarkers in T cells. (a) Representative telomeric repeat amplification protocol (“TRAP”) gel of CD8+ T cells from individual HIV+ donors tested 4 days after activation with anti-CD2/CD3/CD28 microbeads. Lane 1 (+) shows telomerase activity of the Jurkat T cell line. All telomerase activity values from each donor were normalized relative to this positive control. The CD8+ T cell telomerase activity was compared to the percent CD38+. Low %CD38 CD8+ T cells (lanes 2 and 3, with 1.8% and 2.7% CD38+, respectively) have significantly more telomerase activity, indicated visually by the darker bands, than CD8+ T cells with high %CD38+ (lane 1, with 18.5% CD38+). (b) Telomerase activity of CD3+ T cells and the CD8+ T cell subset from HIV+ donors was compared to the %CD38+HLADR+. Statistical analyses showed a strong negative relationship between the %CD38+DR+ cells and telomerase activity of both CD3+ (r = −0.5531, p = 0.0001) and a trend with CD8+ T cells (r = −0.2429, p = 0.1149).
Figure 3 Telomerase activity is inversely correlated with activation biomarkers in T cells. (a) Representative telomeric repeat amplification protocol (“TRAP”) gel of CD8+ T cells from individual HIV+ donors tested 4 days after activation with anti-CD2/CD3/CD28 microbeads. Lane 1 (+) shows telomerase activity of the Jurkat T cell line. All telomerase activity values from each donor were normalized relative to this positive control. The CD8+ T cell telomerase activity was compared to the percent CD38+. Low %CD38 CD8+ T cells (lanes 2 and 3, with 1.8% and 2.7% CD38+, respectively) have significantly more telomerase activity, indicated visually by the darker bands, than CD8+ T cells with high %CD38+ (lane 1, with 18.5% CD38+). (b) Telomerase activity of CD3+ T cells and the CD8+ T cell subset from HIV+ donors was compared to the %CD38+HLADR+. Statistical analyses showed a strong negative relationship between the %CD38+DR+ cells and telomerase activity of both CD3+ (r = −0.5531, p = 0.0001) and a trend with CD8+ T cells (r = −0.2429, p = 0.1149).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 78

Metadata

Authors
Chou, J. P., Ramirez, C. M., Wu, J. E., & Effros, R. B.
Affiliations
University of California, Los Angeles (US)
Corresponding author
Effros, Rita B.
Venue
PLoS ONE
Published
2013-05-22
Volume
8
Issue
5
Pages
e64702
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2051848905
Cited by
78
References
28
Citations by year
2026: 3 · 2025: 5 · 2024: 6 · 2023: 7 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 7 · 2018: 8 · 2017: 10 · 2016: 4 · 2015: 9 · 2014: 7 · 2013: 2
FWCI
3.36
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
  • Deutsches Krebsforschungszentrum
  • National Institutes of Health (-35043, 5-MO1-RR-00722, AI28697, CA16042, UO1-AI-35043)
  • Center for AIDS Research, University of Washington
  • National Institute on Aging (R01AG032422)
  • National Cancer Institute (UO1-AI-35039, CA-16 042, UO1 AI35040, UO1-AI-35042, UO1 AI35041, AI28697, UO1 AI35043, UO1-AI-37984, UO1-AI-37613, 5-MO1-RR-00722, P30CA016042)
  • National Institute of Allergy and Infectious Diseases (UO1-AI 35043, AI35043, U01 AI 35039, UO1 AI37613, AI37984, AI35042, U01 AI 37613, U01-AI-35040, AI35039, U01-AI-37984, AI35041, AI 37613, UO1-AI35040, UO1‐AI‐35041, U01AI35042, U01AI035040, U01AI037984, UO1-AI35039, U01AI035041, U01AI035043, AI-28 697, U01-AI-35041, UO1 AI37984, 5-MO1-RR-00722, U01AI037613, U01AI035039, UO1-AI35042, P30AI028697, U01 AI-35043, U01AI035042, AI35040)
  • National Center for Research Resources (5M01 RR 00722, M01RR000722)
  • Jonsson Comprehensive Cancer Center (AI-28697, CA-16042)
  • David Geffen School of Medicine, University of California, Los Angeles
  • UCLA AIDS Institute
Topics
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
Keywords
HIV-1 infection, CD8+ T cells, replicative senescence, accelerated aging, biomarkers, adenosine deaminase, GLUT1, CD38, telomerase activity, HLA-DR, T cell activation, immune reconstitution, antiretroviral therapy, chronic immune activation
MeSH terms
Aging, Base Sequence, Flow Cytometry, Humans, Middle Aged, Biomarkers, HIV Infections, Cellular Senescence, DNA Primers, CD8-Positive T-Lymphocytes, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.